基础医学与临床 ›› 2013, Vol. 33 ›› Issue (4): 504-507.

• 短篇综述 • 上一篇    下一篇

胰高血糖素样肽-1及类似物对心血管系统作用的研究进展

李礼1,马康华2,罗素新3   

  1. 1. 重庆医科大学附属第一医院心血管内科
    2. 重庆医科大学附属第一医院 心内科
    3. 重庆医科大学附属第一医院
  • 收稿日期:2012-08-30 修回日期:2012-12-07 出版日期:2013-04-05 发布日期:2013-03-15
  • 通讯作者: 罗素新 E-mail:luosuxin0204@163.com

Research progress of glucagon-like peptide-1 and analogues in the cardiovascular system

  • Received:2012-08-30 Revised:2012-12-07 Online:2013-04-05 Published:2013-03-15

摘要: 胰高血糖素样肽-1(GLP-1)因其有效的降糖作用,为临床治疗2型糖尿病带来了新的契机。心血管病变是糖尿病的常见并发症,研究发现GLP-1及类似物可以通过改善内皮功能,抑制炎性反应,减少心梗面积及缺血/再灌注损伤,抑制心肌细胞凋亡和改善心肌能量代谢等作用来降低心血管疾病风险,这将为临床治疗心血管疾病提供新的途径和方法。

关键词: 胰高血糖素样肽-1, 类似物, 心血管系统, 2型糖尿病

Abstract: Glucagon-like peptide-1 (GLP-1) because of its hypoglycemic effect, brings a new occasion to the treatment of type 2 diabetes in clinical practice. Cardiovascular disease is a common complication of diabetes, the study found that GLP-1 and analogs can improve endothelial function, inhibit inflammation, reduce infarct size and ischemia/reperfusion injury, inhibition of cardiomyocyte apoptosis and improve myocardial energy metabolism.These roles can reduce the risk of cardiovascular disease and provide new ways and means for clinical treatment of cardiovascular diseases.

Key words: glucagon-like peptide-1, analogues, cardiovascular system, type 2 diabetes mellitus

中图分类号: